Vaccine-induced neutralizing antibodies against SARS-CoV-2 Omicron variant isolated in Osaka, Japan
Vaccine-induced neutralizing antibodies against SARS-CoV-2 Omicron variant isolated in Osaka, Japan
复制标题
日本大阪分离出针对 SARS-CoV-2 Omicron 变体的疫苗诱导中和抗体
DOI：
10.1099/acmi.0.000465.v3
复制
发表时间：
2023
影响因子：
--
通讯作者：
Mori Haruyo
中科院分区：
文献类型：
--
作者：
Hiroi Satoshi;Morikawa Saeko;Motomura Kazushi;Mori Haruyo
为了研究在日本大阪分离的疫苗诱导的针对严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）变体的中和抗体，对32名接受第二剂疫苗接种的受试者和10名接受第三剂疫苗接种的受试者的血清样本进行了微量中和试验。受试者第二次接种后D614G株、Alpha变异株、Delta变异株和Omicron BA.1的几何平均滴度（GMTs）分别为19.5、21.8、6.3和2.0。δ变异的GMT显著低于D614G株和α变异，而Omicron BA.1的GMT显著低于δ变异。在接受三剂疫苗接种的受试者中，第二次接种后，Omicron BA.1的GMTs（62.8）和ba2的GMTs（38.6）显著高于Omicron BA.1。因此，在本研究中，第二剂疫苗接种诱导了针对SARS-CoV-2菌株的中和抗体，并且被认为通过第三剂疫苗接种增强了中和抗体对变体的反应性。本研究中使用的血清样本将有助于评估疫苗诱导抗体对新出现的变异的反应性。
To study vaccine-induced neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants isolated in Osaka, Japan, microneutralization tests were performed on serum samples from 32 subjects who received a second dose of vaccination, and 10 of those who received the third dose of vaccination. Geometric Mean Titres (GMTs) for the D614G strain, Alpha variant, Delta variant, and Omicron BA.1 of the subjects after the second dose of vaccination were 19.5, 21.8, 6.3, and 2.0, respectively. The GMT for the Delta variant was significantly lower than that for the D614G strain and Alpha variant, and the GMT for the Omicron BA.1 was significantly lower than that for the Delta variant. Among the subjects who received three doses of vaccination, the GMTs for the Omicron BA.1 (62.8) and BA.2 (38.6) were significantly higher than that for the Omicron BA.1 after the second dose. Thus, in the present study, the second dose of vaccination induced neutralizing antibodies against SARS-CoV-2 strains, and the reactivity of neutralizing antibodies to the variants was thought to be enhanced by the third dose of vaccination. The serum samples used in this study will be useful in evaluating the reactivity of vaccine-induced antibodies to newly emerging variants.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1056/nejmoa2119451
发表时间：
2022-04-21
期刊：
The New England journal of medicine
影响因子：
--
作者：
Andrews N;Stowe J;Kirsebom F;Toffa S;Rickeard T;Gallagher E;Gower C;Kall M;Groves N;O'Connell AM;Simons D;Blomquist PB;Zaidi A;Nash S;Iwani Binti Abdul Aziz N;Thelwall S;Dabrera G;Myers R;Amirthalingam G;Gharbia S;Barrett JC;Elson R;Ladhani SN;Ferguson N;Zambon M;Campbell CNJ;Brown K;Hopkins S;Chand M;Ramsay M;Lopez Bernal J
通讯作者：
Lopez Bernal J
Nishiyama R、Nakamura S、Suzuki S 等人：“肝缺血/再灌注损伤中的血小板激活因子 (PAF)。-PAF 拮抗剂与前列腺素 I_2 类似物联合的效果-”移植。
DOI：
--
发表时间：
--
期刊：
影响因子：
--
作者：
通讯作者：
--
mRNA疫苗会诱导SARS-COV-2和关注的变体诱导耐用的免疫记忆。
DOI：
10.1126/science.abm0829
发表时间：
2021-12-03
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
通讯作者：
--
埃塞俄比亚 新型冠状病毒（COVID-19）情况报告
DOI：
--
发表时间：
2020
期刊：
--
影响因子：
--
作者：
J. Chung;A. Metzger;N. Asakura;M. Sarr;E. Dimagno
通讯作者：
E. Dimagno